Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Chrolavicius

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
American Heart Journal|December 13, 2005
Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes, Shamir R Mehta, Salim Yusuf, et al.
European Heart Journal|February 5, 2008
The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trialRon J G Peters, Campbell Joyner, Jean-Pierre Bassand, et al.
Annals of Internal Medicine|September 6, 2007
Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromesKeith A A Fox, Jean-Pierre Bassand, Shamir R Mehta, et al.
Circulation|July 31, 2015
Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation: Incidence, Risk Factors, and OutcomesWobo Bekwelem, Stuart J Connolly, Jonathan L Halperin, et al.
JAMA|November 29, 2007
Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarctionRafael Díaz, Abhinav Goyal, Shamir R Mehta, et al.
JAMA|March 16, 2006
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trialSalim Yusuf, Shamir R Mehta, Susan Chrolavicius, et al.
The New England Journal of Medicine|March 16, 2006
Comparison of fondaparinux and enoxaparin in acute coronary syndromes, Salim Yusuf, Shamir R Mehta, et al.
European Heart Journal|October 15, 2009
Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromesJean-Pierre Bassand, Rizwan Afzal, John Eikelboom, et al.
American Heart Journal|December 15, 2010
Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): a randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinuxPhilippe Gabriel Steg, Shamir Mehta, Sanjit Jolly, et al.
American Heart Journal|December 17, 2011
Rationale and design of the coronary artery bypass grafting surgery off or on pump revascularization study: a large international randomized trial in cardiac surgeryAndre Lamy, Philip J Devereaux, Dorairaj Prabhakaran, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
American Heart Journal|December 13, 2005
Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes, Shamir R Mehta, Salim Yusuf, et al.
European Heart Journal|February 5, 2008
The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trialRon J G Peters, Campbell Joyner, Jean-Pierre Bassand, et al.
Annals of Internal Medicine|September 6, 2007
Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromesKeith A A Fox, Jean-Pierre Bassand, Shamir R Mehta, et al.
Circulation|July 31, 2015
Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation: Incidence, Risk Factors, and OutcomesWobo Bekwelem, Stuart J Connolly, Jonathan L Halperin, et al.
JAMA|November 29, 2007
Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarctionRafael Díaz, Abhinav Goyal, Shamir R Mehta, et al.
JAMA|March 16, 2006
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trialSalim Yusuf, Shamir R Mehta, Susan Chrolavicius, et al.
The New England Journal of Medicine|March 16, 2006
Comparison of fondaparinux and enoxaparin in acute coronary syndromes, Salim Yusuf, Shamir R Mehta, et al.
European Heart Journal|October 15, 2009
Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromesJean-Pierre Bassand, Rizwan Afzal, John Eikelboom, et al.
American Heart Journal|December 15, 2010
Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): a randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinuxPhilippe Gabriel Steg, Shamir Mehta, Sanjit Jolly, et al.
American Heart Journal|December 17, 2011
Rationale and design of the coronary artery bypass grafting surgery off or on pump revascularization study: a large international randomized trial in cardiac surgeryAndre Lamy, Philip J Devereaux, Dorairaj Prabhakaran, et al.
Pageof 4